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Background: High mobility group box protein 1 (HMGB1) is a transcriptional regulator that is receiving increasing
attention in autoimmune disorders including multiple sclerosis (MS). Here, we investigated the role of HMGB1 in
the peripheral blood compartment from MS patients.
Methods: HMGB1 mRNA expression levels were determined by PCR in peripheral blood mononuclear cells (PBMC) of 29
healthy controls and 57 untreated MS patients (26 with relapsing-remitting MS - RRMS, 13 with secondary progressive
MS - SPMS, and 18 with primary progressive MS - PPMS). HMGB1 protein levels were measured by ELISA in serum samples
from 18 HC and 37 untreated MS patients (13 with RRMS, 14 with SPMS, and 10 with PPMS).
Results: HMGB1 expression levels were increased in PBMC from the whole MS group compared with controls (P = 0.03).
Further stratification of the MS group revealed higher expression levels in PBMC from patients with relapse-onset MS, and
differences were statistically significant for RRMS patients compared with PPMS patients and controls (P = 4 × 10−5 and
P = 0.005, respectively) and also for SPMS patients compared with PPMS patients (P = 0.001). HMGB1 serum levels were
increased in the whole MS group compared with controls (P = 2 × 10−4). In MS clinical forms, the highest HMGB1 serum
levels were observed in RRMS patients, and differences were statistically significant compared to PPMS patients
(P = 5 × 10−5), SPMS patients (P = 0.001), and controls (P = 0.001).
Conclusions: These results point to a role of HMGB1 mRNA and protein levels as disease activity biomarkers to
discriminate the more inflammatory relapse-onset MS forms, particularly RRMS, from the less inflammatory PPMS form of
the disease.
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High mobility group box protein 1 (HMGB1) is a DNA-
binding non-histone protein that acts as a transcriptional
regulator and nucleosomal stabilizer [1,2]. It is released
from activated immune cells, necrotic cells, and apoptotic
cells and during secondary necrosis [3]. HMGB1 may
drive pro-inflammatory responses through binding to cell-
surface receptors such as the receptor of advanced glyca-
tion end products (RAGE) and the Toll-like receptors
(TLR)-2, TLR-4, and TLR-9 [3]. Increasing evidence exists* Correspondence: manuel.comabella@vhir.org
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unless otherwise stated.for a role of HMGB1 in autoimmune disorders. In this
context, recent studies have shown associations between
HMGB1 and rheumatoid arthritis [4], systemic lupus ery-
thematosus [5], psoriasis [6], and Sjögren’s syndrome [7].
In multiple sclerosis (MS), HMGB1 expression was found
to be upregulated in brain active lesions from patients [8].
In the animal model of MS, experimental autoimmune en-
cephalomyelitis (EAE), neutralization of HMGB1 amelio-
rated clinical severity, reduced central nervous system
pathology, and blocked pro-inflammatory cytokine pro-
duction [9,10].
Based on these observations, in the present study, we
aimed to investigate a potential role of HMGB1 in the per-
ipheral blood compartment by determining its expression inal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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levels of HMGB1 in MS patients with different clinical
forms and healthy controls.
Methods
Determination of HMGB1 expression levels in PBMC by
real-time PCR
mRNA expression levels for HMGB1 were determined
in PBMC from 57 untreated MS patients and 29 healthy
controls (HC). The MS group comprised 26 patients
with relapsing-remitting MS (RRMS), 13 patients with
secondary progressive MS (SPMS), and 18 patients with
primary progressive MS (PPMS). Table 1 shows a sum-
mary of demographic and clinical characteristics of MS
patients and controls included in the study.
PBMC were isolated by Ficoll-Isopaque density gradient
centrifugation (Gibco BRL, Life Technologies LTD, Paisley,
UK) and stored in liquid nitrogen until used. Total RNA
was extracted from PBMC using an RNeasy kit (Qiagen,
Santa Clarita, USA) and cDNA synthesized using the High
Capacity cDNA Archive Kit (Applied Biosystems, Foster
City, CA, USA). HMGB1 transcripts were determined with
TaqMan® gene expression assays (Hs01590761_g1; Applied
Biosystems). The housekeeping gene glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used as an en-
dogenous control (Applied Biosystems). Assays were run
on the ABI PRISM® 7900HT system (Applied Biosystems)
and data were analyzed with the 2−ΔΔCT method [11]. Re-
sults were expressed as fold change in gene expression in
MS patients or clinical forms of MS relative to healthy con-
trols (calibrators).
Quantification of HMGB1 levels in serum samples by
ELISA
Serum levels of HMGB1 were measured in serum samples
from 37 untreated MS patients and 18 healthy controls.
The MS group included 13 patients with RRMS, 14 pa-
tients with SPMS, and 10 patients with PPMS. Table 2Table 1 Demographic and baseline clinical characteristics of M
expression study
Baseline characteristics HC MSd
Number of patients 29 57
Age (years) 40.0 (9.1) 43.0 (9.9
Female/male (% women) 13/16 (44.8) 31/26 (5
Duration of disease (years) - 9.2 (6.0)
EDSSa - 3.9 (2.0-
Number of relapsesb - 1.4 (0.9)
Number of Gd-enhancing lesionsc - 0.9 (1.9)
Data are expressed as mean (standard deviation) unless otherwise stated. aData are ex
two previous years of blood extraction. cRefers to the number of gadolinium-enhancin
concomitant lupus anticoagulant. One SPMS patient had a past history of uveitis and b
month prior to blood extraction for mRNA determination. Information is missing for eig
patients. EDSS: Expanded Disability Status Scale. RRMS: relapsing-remitting MS. SPMS: ssummarizes demographic and clinical characteristics of MS
patients and controls included in this part of the study.
Eleven patients with RRMS (84.6%), five patients with
SPMS (35.7%), and eight patients with PPMS (80%) were
also used in the HMGB1 expression study. None of the 14
healthy controls included in the ELISA study was used in
the expression study. Demographic and clinical characteris-
tics were comparable for all variables between both cohorts
(Additional file 1: Table S1).
Peripheral blood was collected by standard venipuncture
and allowed to clot spontaneously for 30 min. Serum was
isolated by centrifugation and stored frozen at −80°C until
used. Levels of HMGB1 were measured in serum sam-
ples by means of a commercially available ELISA (Hu-
man HMGB1 ELISA; IBL International GMBH,
Hamburg, Germany). All samples were measured in
duplicate in undiluted serum samples. The intra-assay
and inter-assay coefficients of variation were 2.1% and
1.1%, respectively.Statistical analysis
Statistical analysis was performed by using the SPSS 17.0
package (SPSS Inc, Chicago, IL) for MS Windows. Com-
parisons of mRNA expression levels and serum levels of
HMGB1 between MS patients and healthy controls and
between different clinical forms of MS, and correlations
with clinical and radiological variables were performed
by parametric and non-parametric tests depending on
the applicability conditions. Bonferroni correction was
used to correct the alpha level for multiple comparisons
between MS patients with different clinical forms of the
disease (alpha = 0.008).Ethics statement
The study was approved by the Hospital Universitari
Vall d’Hebron ethics committee, and all patients gave
their informed consent.S patients and healthy controls included in the HMGB1
RRMS SPMS PPMS
26 13 18
) 36.8 (7.8) 45.7 (6.5) 49.9 (9.5)
4.4) 16/10 (61.5) 8/5 (61.5) 7/11 (38.9)
5.7 (4.5) 10.9 (6.3) 10.6 (6.0)
5.9) 1.9 (1.0-2.0) 4.2 (3.5-5.3) 5.3 (4.3-6.5)
1.7 (0.7) 1.1 (1.0) -
1.0 (2.0) 0.7 (1.9) -
pressed as mean (interquartile range). bRefers to the number of relapses in the
g lesions at the time of blood extraction. dOne RRMS patient had a history of
reast cancer. One RRMS patient received corticosteroid treatment within the
ht patients (seven PPMS and one SPMS). MS: refers to the whole group of MS
econdary progressive MS. PPMS: primary progressive MS. HC: healthy controls.
Table 2 Demographic and baseline clinical characteristics of MS patients and healthy controls included in the ELISA study
Baseline characteristics HC MSd RRMS SPMS PPMS
Number of patients 18 37 13 14 10
Age (years) 42.8 (10.6) 43.6 (9.7) 36.0 (8.0) 44.7 (7.6) 51.9 (6.5)
Female/male (% women) 9/9 (50.0) 22/15 (59.5) 8/5 (61.5) 9/5 (64.3) 5/5 (50.0)
Duration of disease (years) - 8.3 (5.0) 6.1 (4.4) 8.8 (4.0) 10.1 (5.6)
EDSSa - 3.9 (2.3-5.3) 2.2 (1.5-3.0) 4.5 (4.0-5.1) 5.4 (4.3-6.5)
Number of relapsesb - 1.1 (0.9) 1.6 (0.8) 0.6 (0.8) -
Number of Gd-enhancing lesionsc - 1.4 (2.8) 1.7 (3.2) 1.0 (2.2) -
Data are expressed as mean (standard deviation) unless otherwise stated. aData are expressed as mean (interquartile range). bRefers to the number of relapses in the
two previous years of blood extraction. cRefers to the number of gadolinium-enhancing lesions at the time of blood extraction. dOne SPMS patient had a history of
concomitant gastritis. One RRMS patient received corticosteroid treatment within the month prior to blood extraction for protein determination. Information is missing
for five patients (four PPMS and one SPMS). MS: refers to the whole group of MS patients. EDSS: Expanded Disability Status Scale. RRMS: relapsing-remitting MS. SPMS:
secondary progressive MS. PPMS: primary progressive MS. HC: healthy controls.
Malhotra et al. Journal of Neuroinflammation  (2015) 12:48 Page 3 of 5Results
HMGB1 gene expression levels are increased in patients
with relapse-onset forms of MS
We first compared mRNA expression levels for HMGB1
between the whole group of MS patients and healthy
controls. As shown in Figure 1A, HMGB1 expression
was significantly increased in PBMC from MS patients
compared to controls (P = 0.03). When we segregated
patients on the basis of clinical forms (Figure 1B),
HMGB1 expression levels were higher in PBMC from
patients with relapse-onset MS, and differences were sta-
tistically significant for RRMS patients when compared
both with PPMS patients and controls (P = 4 × 10−5 and
P = 0.005, respectively), and also for SPMS patients when
compared with PPMS patients (P = 0.001). A trend to-
wards increased mRNA expression levels of HMGB1
was observed in SPMS patients when compared with
controls (P = 0.05). HMGB1 expression levels were simi-


























Figure 1 Bar graphs comparing HMGB1 mRNA expression levels in PB
different clinical forms of MS (B). HMGB1 expression was determined by r
as fold change in HMGB1 gene expression in MS patients relative to controls.
included in the study is shown in parentheses. HC: healthy controls. MS: whol
secondary progressive MS. PP: primary progressive MS.HMGB1 serum levels are elevated in relapse-onset MS
As shown in Figure 2A, HMGB1 protein levels paralleled
HMGB1 mRNA expression levels, and serum levels were
significantly increased in the whole MS group compared
to the healthy control group (P = 2 × 10−4). When MS pa-
tients were stratified according to the different clinical
forms, the highest HMGB1 serum levels were observed in
patients with RRMS, and differences were statistically sig-
nificant compared to PPMS patients (P = 5 × 10−5), SPMS
patients (P = 0.001), and healthy controls (P = 0.001)
(Figure 2B). In the SPMS group, statistically significant dif-
ferences were only observed with the healthy control group
(P = 0.007) but not with the PPMS group (P = 0.1). A trend
towards increased serum levels of HMGB1 was observed in
PPMS patients compared with controls (P = 0.01).
Correlations between HMGB1 levels and clinical and
radiological variables
No statistically significant correlations were observed be-


























(N=29) (N=26) (N=13) (N=18)
B
MCs from MS patients and healthy controls (A) and between
eal-time PCR using GAPDH as endogenous control. Results are expressed
Errors bars represent standard error of the mean. Number of individuals
















































Figure 2 Box plots showing serum levels of HMGB1 in the whole MS group and controls (A) and in MS patients with different clinical
forms of MS (B). Serum levels of HMGB1 were measured using a commercially available ELISA, as described in ‘Methods.’ For the sake of clarity,
only significant P values are shown in the graphs. Number of individuals included in the study is shown in parentheses. Eleven patients with
RRMS, five with SPMS, and eight with PPMS were also included in the HMGB1 gene expression study. HC: healthy controls. MS: whole group of
multiple sclerosis patients. RR: relapsing-remitting MS. SP: secondary progressive MS. PP: primary progressive MS.
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variables (disease duration, number of relapses in the
previous 2 years, and EDSS score at the time of blood col-
lection) nor with radiological variables (number of
gadolinium-enhancing lesions at the time of blood extrac-
tion) (data not shown).
Discussion
HMGB1 has a dual role. In addition to contribute to nu-
clear homeostasis by acting as a transcriptional regulator
and nucleosome stabilizer [1,2], HMGB1 can also play a
role as a cytokine by being passively released from apop-
totic/necrotic cells or actively secreted from monocytes,
and subsequently binding to receptors such as RAGE,
TLR-2, and TLR-4 [12,13]. In this context, HMGB1 has
been shown to mediate pro-inflammatory cytokine pro-
duction [14], T cell proliferation [15], and cell migration
[16], actions that can certainly be pathogenically relevant
for autoimmune disorders like MS.
In the present study, we found that MS patients
showed increased mRNA and protein levels of HMGB1
as compared to healthy controls. Within the MS group,
differences were driven by patients with relapse-onset
MS, particularly by patients with RRMS. Both mRNA
and protein levels for HMGB1 were clearly elevated in
RRMS patients compared to controls and PPMS pa-
tients. At the protein level, differences were also ob-
served between the RRMS and SPMS groups. It should
be mentioned that one of the limitations of the study
was the low number of patients in individual groups, al-
though the statistical differences in mRNA and protein
levels between groups were strong enough to survive
Bonferroni correction.
Studies on HMGB1 are scarce in MS. HMGB1 expres-
sion was found to be upregulated in macrophages andmicroglia from actively demyelinating MS lesions [8]. In
this same study, HMGB1 gene expression was also mea-
sured in cerebrospinal fluid (CSF) cells and PBMC from a
small cohort of MS patients and non-inflammatory
neurological controls, and mRNA expression levels
were higher in CSF cells from MS patients compared
with controls whereas no significant differences were
observed in PBMC [8]. Factors mainly related to study
design may well explain the discrepancies observed
with the present study: inclusion of a subgroup of
RRMS patients during relapse, lack of further stratifica-
tion of the MS group into RRMS and SPMS patients
for HMGB1 comparisons among groups, or lumping non-
inflammatory neurological controls and healthy controls
within a unique control group [8].
In SPMS patients, more prominent HMGB1 differences
were observed at the mRNA than at the protein level.
Whereas HMGB1 mRNA expression levels in SPMS pa-
tients were similar to those seen in RRMS patients and
significantly higher compared to PPMS patients, HMGB1
protein levels were lower in the SPMS group than in the
RRMS group and significant differences were lost with
PPMS patients. Although the reasons for these differences
are possibly manifold, the inclusion of a largely independ-
ent cohort of SPMS patients (64%) with less active disease
for HMGB1 protein quantification may have contributed
to the finding of lower protein levels compared to mRNA
expression levels in this group of patients (mean number
of relapses in the two previous years: 0.6 in the SPMS co-
hort used for protein determination versus 1.1 in the
SPMS cohort used for mRNA quantification).
Finally, the group of patients with PPMS contributed lit-
tle to the significant differences observed in mRNA and
protein levels of HMGB1 between MS patients and con-
trol individuals. In fact, MS patients having this less
Malhotra et al. Journal of Neuroinflammation  (2015) 12:48 Page 5 of 5inflammatory form of the disease behaved largely similar
to the healthy control group in terms of HMGB1 mRNA
and protein levels.
In conclusion, these results point to a role of HMGB1
in MS, particularly in patients with RRMS and SPMS.
The mRNA expression levels in PBMC or serum levels
of HMGB1 may be used as disease activity biomarkers
to discriminate the more inflammatory relapse-onset
forms of MS from the less inflammatory PPMS form of
the disease.
Additional file
Additional file 1: Table S1. Comparisons for demographic and clinical
variables between the two cohorts of patients included in the study.
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